Business
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the fourth quarter and full-year 2025 financial results and provided a summary of recent developments. “2025 was a productive year for Monopar, marked by multiple ALXN1840 data presentations, an important publication, a strengthened balance sh
About this update from Monopar Therapeutics Inc.
[{"type":"image","alt":"Monopar Therapeutics Inc.","displaySize":"","headline":null,"caption":"Monopar Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/78ad59c9c1072dda3cd2bbfc9abc4430"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8kyzQtbKIBMgzTjovzij7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4/https://media.zenfs.com/en/globenewswire.com/78ad59c9c1072dda3cd2bbfc9abc4430","width":300,"height":56}},"lazy":false},{"type":"text","content":"WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the fourth quarter and full-year 2025 financial results and provided a summary of recent developments.","length":359,"tagName":"p"},{"type":"text","content":"“2025 was a productive year for Monopar, marked by multiple ALXN1840 data presentations, an important publication, a strengthened balance sheet and continued progress toward a planned New Drug Application submission for ALXN1840 in Wilson disease,” said Chandler Robinson, MD, Chief Executive Officer of Monopar. “We also recently strengthened our leadership team with the addition of Susan Rodriguez as Chief Commercial and Strategy Officer as we prepare for the potential launch of ALXN1840. We are grateful to the Wilson disease patients and their families whose experiences have informed our efforts to advance ALXN1840.”","length":625,"tagName":"p"},{"type":"text","content":"Recent Program Developments","length":27,"tagName":"p"},{"type":"text","content":"ALXN1840 – NDA Submission Planned for Mid-2026 for Wilson Disease","length":65,"tagName":"p"},{"type":"text","content":"Wilson disease is a rare genetic disorder characterized by impaired copper elimination, resulting in toxic accumulation in organs such as the liver and brain. ALXN1840 binds and mobilizes copper and has a novel mechanism of action as an albumin tripartite complex (“ATC”) activator that differentiates it from currently available first-line therapies.","length":351,"tagName":"p"},{"type":"text","content":"Based on recent interactions with the U.S. Food and Drug Administration (“FDA”), Monopar plans to submit a New Drug Application (“NDA”) f...